Emergent buys ABEC bioreactor to transfer raxibacumab to Baltimore facility

By Gareth Macdonald 

Bioterrorism countermeasure manufacturer Emergent Biosciences has bought a 4,000L bioreactor developed by ABEC.

https://www.biopharma-reporter.com/article/2017/10/27/emergent-buys-abec-bioreactor-to-transfer-raxibacumab-to-baltimore-facility